VENERA MILLER: Open Payments
NPI 1053349902 · PRINCE FREDERICK, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,555 in 83 payments from 12 companies in 2025. Trend: 2023 $1,044 · 2024 $1,261 · 2025 $1,555
Food & beverage: $1,543Education: $12
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $284 |
| Vanda Pharmaceuticals Inc. | 14 | $267 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $248 |
| Indivior Inc. | 8 | $193 |
| Lundbeck LLC | 7 | $140 |
| Otsuka America Pharmaceutical, Inc. | 5 | $96 |
| Supernus Pharmaceuticals, Inc. | 4 | $86 |
| Alkermes, Inc. | 4 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $79 |
| Axsome Therapeutics, Inc. | 3 | $49 |
Products named: VRAYLAR, CAPLYTA, REXULTI, SUBLOCADE, HETLIOZ, FANAPT, Qelbree, ARISTADA.
Industry payments across MD — which companies pay providers there.
